The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue

Cancer

Volumn 86, Issue 6, 1999, Pages 913-920

  Xie, Xin ^a   Clausen, Ole Petter F ^a   De Angelis, Paula ^a   Boysen, Morten ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apoptosis; Bax; Bcl 2; P53; Prognosis; Tongue squamous cell carcinoma

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033567933     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990915)86:6<913::AID-CNCR4>3.0.CO;2-A     Document Type: Article

References (47)

1. Næss Å. Incidence and survival of Norwegian head and neck cancer patients in six five-year periods from 1960 to 1989. Output from the database at the Norwegian Cancer Registry. Oslo: The Norwegian Cancer Registry, 1991.
2. Searle J, Collins DJ, Harmon B, Kerr JF. The spontaneous occurrence of apoptosis in squamous carcinomas of the uterine cervix. Pathology 1973;5:163-9.
3. Wyllie AH. The biology of cell death in tumours. Anticancer Res 1985;5:131-6.
4. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
5. Hockenbery DM. Bcl-2 in cancer, development and apoptosis. J Cell Sci 1994;18:51-5.
6. Boise LH, Gottschalk AR, Quintans J, Thompson CB. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Curr Top Microbiol Immunol 1995;200:107-21.
7. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
8. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994;79:189-92.
9. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995;9:451-73.
10. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEH 17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407-11.
11. Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, et al. Induction of the death-promoting gene bax-alpha sensitizes cultured breast cancer cells to drug-induced apoptosis. Int J Cancer 1996;67:138-41.
12. Sakakura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Nakatani H, et al. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 1996;67:101-5.
13. Kitada S, Krajewski S, Miyashita T, Krajewska M, Reed JC. Gamma-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Oncogene 1996;12:187-92.
14. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995;177:49-55.
15. Wilson GD, Grover R, Richman PI, Daley FM, Saunders MI, Dische S. Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 1996;16:2403-8.
16. Ohbu M, Saegusa M, Kobayashi N, Tsukamoto H, Mieno H, Kakita A, et al. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer 1997;79:1287-93.
17. Friedman M, Grey P, Venkatesan TK, Bloch I, Chawla P, Caldarelli DD, et al. Prognostic significance of Bcl-2 expression in localized squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol 1997;106:445-50.
18. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, et al. Reduced expression of proapoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55: 4471-8.
19. Xie X, Clausen OPF, De Angelis P, Boysen M. Bax expression has prognostic significance that is enhanced when combined with AgNOR counts in glottic carcinomas. Br J Cancer 1998;78:100-5.
20. Marx D, Binder C, Meden H, Lenthe T, Ziemek T, Hiddemann T, et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997;17:2233-40.
21. Gazzaniga P, Gradilone A, Vercillo R, Gandini O, Silvestri I, Napolitano M, et al. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer 1996;69:100-4.
22. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
23. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992;71:543-6.
24. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352:345-7.
25. Attardi LD, Lowe SW, Brugarolas J, Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 1996; 15:3693-701.
26. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
27. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, et al. Immediate early up-regulation of bax expression by p53 but not TGFβ1: a paradigm for distinct apoptotic pathways. Oncogene 1994;9:1791-8.
28. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
29. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73: 181-6.
30. Nylander K, Stenling R, Gustafsson H, Zackrisson B, Roos G. p53 expression and cell proliferation in squamous cell carcinomas of head and neck. Cancer 1995;75:87-93.
31. Caminero MJ, Nunez F, Suarez C, Ablanedo P, Riera JR, Dominguez F. Detection of p53 protein in oropharyngeal carcinoma: prognostic implications. Arch Otolaryngol Head Neck Surg 1996;122:769-72.
32. Hirvikoski P, Kumpulainen E, Virtaniemi J, Johansson R, Haapasalo H, Marin S, et al. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol 1997;15:3111-20.
33. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998;110:443-9.
34. Eid H, Gulyas M, Geczi L, Bodrogi I, Institoris E, Bak M. Expression of bcl-2 in testicular carcinoma: correlation with tumor progression and MDR1/Pgp. Cancer 1998;83:331-6.
35. Tollenaar RA, van Krieken JH, van Slooten HJ, Bruinvels DJ, Nelemans KM, van den Broek LJ, et al. Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer 1998;77: 1842-7.
36. Koshida Y, Saegusa M, Okayasu I. Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 1997;75:367-73.
37. Hagedorn HG, Tubel J, Wiest I, Nerlich AG. In situ apoptotic and proliferation index in laryngeal squamous cell carcinomas. Anal Cell Pathol 1998;16:177-84.
38. Levine EL, Renehan A, Gossiel R, Davidson SE, Roberts SA, Chadwick C, et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995;37:1-9.
39. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, et al. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res 1998;18:1989-98.
40. Langlois NE, Lamb J, Eremin O, Heys SD. Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 protein products. J Pathol 1997;182:392-7.
41. Sugamura K, Makino M, Kaibara N. Apoptosis as a prognostic factor in colorectal carcinoma. Surg Today 1998;28:145-50.
42. Harrison DJ. Counting apoptosis - why and how? J Clin Pathol (Clin Mol Pathol) 1996;49:M245-6.
43. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is universal inhibitor of cyclin kinases. Nature 1993; 366:701-4.
44. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, et al. Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen. Science 1994;266:1376-80.
45. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
46. Hall PA, McKee PH, Menage HDP, Dover R, Lane DP. High levels of p53 proteins in UV-irradiated normal human skin. Oncogene 1993; 8:203-7.
47. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.